Amanote Research
Register
Sign In
A Multi-Institutional, Phase II Open-Label Study of Ganitumab (AMG 479) in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Endocrine-Related Cancer
- United Kingdom
doi 10.1530/erc-12-0390
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Endocrinology
Oncology
Metabolism
Diabetes
Date
April 9, 2013
Authors
J R Strosberg
J A Chan
D P Ryan
J A Meyerhardt
C S Fuchs
T Abrams
E Regan
R Brady
J Weber
T Campos
L K Kvols
M H Kulke
Publisher
Bioscientifica
Related search
Prognosis of Sporadic Resected Small (≤2 Cm) Nonfunctional Pancreatic Neuroendocrine Tumors – A Multi-Institutional Study
HPB
Hepatology
Gastroenterology
A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients With Advanced Malignant Tumors
Clinical Cancer Research
Cancer Research
Oncology
Pancreatic Neuroendocrine Tumors
Revista Espanola de Enfermedades Digestivas
Medicine
Gastroenterology
Sunitinib in Advanced Pancreatic Neuroendocrine Tumors: Latest Evidence and Clinical Potential
Therapeutic Advances in Medical Oncology
Oncology
OA13 High-Dose Icotinib in Advanced NSCLC With EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Gemcitabine and Oxaliplatin (GEMOX) in Gemcitabine Refractory Advanced Pancreatic Adenocarcinoma: A Phase II Study
British Journal of Cancer
Cancer Research
Oncology
Molecular Pathogenesis of Pancreatic Neuroendocrine Tumors
Cancers
Cancer Research
Oncology
Promising Developments for Pancreatic Neuroendocrine Tumors
Cancer Discovery
Oncology
Sunitinib in Pancreatic Neuroendocrine Tumors. Clinical Case
Medical Council
